Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
The treatment aims for type 2 diabetes are to prevent complications and premature mortality, and improve quality of life. Glycaemic control is central to these aims; clinical guidelines have sought to achieve this with a stepwise approach starting with lifestyle measures and metformin, adding further medications once glycated haemoglobin (HbA1c) levels rise above a predefined threshold. However, treatment intensification can be delayed when HbA1c levels increase, and HbA1c levels become inadequately controlled in many patients. Clinical inertia can result in sustained elevated levels of HbA1c; when combined with a late diagnosis, this negatively impacts patients’ prognosis. Early combination therapy using medications with complementary modes of action could achieve optimal glycaemic targets and alter the course of the disease more than metformin alone. The multinational VERIFY study (clinicaltrials.gov NCT01528254) provided evidence accrued over 5 years, demonstrating the potential of early combination therapy: time to loss of glycaemic control was nearly doubled, and more than twice the number of patients experienced extended glycaemic control, with a vildagliptin–metformin combination therapy versus metformin alone. The study also showed a delay in secondary treatment failure in patients receiving the combination. Early combination therapy therefore offers a different trajectory to the stepwise approach. Translating these findings into clinical practice will require early detection and diagnosis of type 2 diabetes plus a shift in disease management. Nonetheless, the potential benefits of sustained and continuous disease control that early combination therapy offers represent the start of a new era in early diagnosis and intensive management, to achieve the treatment aims of type 2 diabetes. Blood glucose progressively increases over time in type 2 diabetes and is currently treated in a stepwise fashion, with more medications added when a single treatment fails. The VERIFY trial studied people with newly or recently diagnosed type 2 diabetes. Treating people early with two glucose-lowering drugs given together could slow the worsening of blood glucose levels, compared with starting with metformin first and then adding a second treatment later. Taking the two treatments together was as well tolerated as taking the single treatment alone. Starting treatment with two glucose-lowering drugs given together lengthened the time before insulin was needed, compared with starting with metformin and then adding a second treatment later. This is important to people with diabetes, as early treatment is straightforward but becomes increasingly complicated in later stages. The long-term benefits of this early combination treatment are awaited. In the meantime, the VERIFY trial has shown that combination therapy given at the start of treatment with medication can improve blood glucose levels and delay the need for insulin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 An abbreviated overview of ADA and EASD recommendations over the last decade for stepwise therapy for patients with type 2 diabetes. 1Nathan DM, et al. Diabetologia 2009;52:17–30 [4]. 2Inzucchi SE, et al. Diabetologia 2012;55:1577–96 [6]. 3Inzucchi SE, et al. Diabetologia 2015;58:429–42 [5]. 4Davies MJ, et al. Diabetologia 2018;61:2461–98 [1]. 5Buse JB, et al. Diabetologia 2020;63:221–8 [7]. *Well-validated core therapies. †GLP-1 receptor agonist not to be used with either a DPP4 inhibitor or an SGLT2 inhibitor. ADA American Diabetes Association, ASCVD atherosclerotic cardiovascular disease, CKD chronic kidney disease, CVD cardiovascular disease, EASD European Association for the Study of Diabetes, HbA1c glycated haemoglobin](https://figures.cochat.ai/paper-figures/e3537b8a44b148d8bb43d42883b2e35e/insights-from-verify-early-combination-therapy-provides-better-glycaemic-figure-1.jpg)
![Fig. 2 The VERIFY study design. Adapted from Del Prato S, et al. Diabet Med. 2014;31;1178–84 [16]](https://figures.cochat.ai/paper-figures/7dba203d2da84393acdd3ee0143bcdf1/insights-from-verify-early-combination-therapy-provides-better-glycaemic-figure-2.jpg)
![Fig. 3 A 26% reduction in risk of time to secondary treatment failure following early combination therapy in the VERIFY study [14]; i.e. approx. 1 in 4 patients treated and initially experiencing failure with early combination treatment did not require addition of a third treatment (usually insulin), versus delayed combination therapy. *Defined as loss of glycaemic control: two consecutive values of HbA1c ≥ 53 mmol/mol (7.0%). †Defined by the need to maintain glycaemic control with a third treatment (usually insulin) in patients receiving combination therapy, according to local diabetes treatment guidelines and as per investigators discretion](https://figures.cochat.ai/paper-figures/3912d25d774f4199bfcf74714c17f9d0/insights-from-verify-early-combination-therapy-provides-better-glycaemic-figure-3.jpg)
![Fig. 4 Early combination strategy and evolution of the patient journey from early diagnosis of type 2 diabetes. Adapted from Reach G, et al. Diabetes Metab. 2017;43:501–11, Strain WD, et al. Diabetes Res Clin Pract. 2014;105:302–12 and Pantalone KM, et al. Diabetes Care. 2016;39:1527–34 [10–12]](https://figures.cochat.ai/paper-figures/b42d008cb4754e55ad7aea832f9c8ce5/insights-from-verify-early-combination-therapy-provides-better-glycaemic-figure-4.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early combination therapy based on the perceived need for additional glycemic ef fi cacy or cardiorenal protection can be considered at treatment initiation to extend the time to treatment failure (176).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [176]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationGupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Self-citation
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
“Early combination therapy based on the perceived need for additional glycemic efficacy or cardiorenal protection can be considered at treatment initiation to extend the time to treatment failure (176).”
BackgroundSelf-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
“on the perceived need for additional glycaemic efficacy or cardiorenal protection can be considered at treatment initiation to extend the time to treatment failure [176].”
Self-citationSeidu, S., Alabraba, V., Davies, S., Newland‐Jones, P., Fernando, K., Bain, S. C., Diggle, J., Evans, M., James, J., Kanumilli, N., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01550-5 · Cited by 97
Aroda, V. R., & Eckel, R. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14830 · Cited by 43
“treatment failure) and also reduced the risk of time to secondary treatment failure by 26%.(105,106) Although the trial was not powered to assess CV outcomes, early combination therapy was associated with a numerically longer time to first adjudicated macrovascular event than metformin monotherapy.”
BackgroundMohan, V., Zargar, A. H., Chawla, M. S., Joshi, A. S., Ayyagari, U., Sethi, B. K., Gaurav, K., Patted, U. R. H., Bhagat, S. V., & Mane, A. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s315227 · Cited by 25
Self-citation
Metadata
- Authors
- Matthews, D., Del Prato, S., Mohan, V., Mathieu, C., Vencio, S., Chan, J. C. N., Stumvoll, M., & Paldánius, P. M.
- Affiliations
- University of Oxford (GB)
- Madras Diabetes Research Foundation (IN)
- Universitair Ziekenhuis Leuven (BE)
- Chinese University of Hong Kong (HK)
- Novartis (Switzerland) (CH)
- Corresponding author
- Matthews, David
- Venue
- Diabetes Therapy
- Published
- 2020-09-25
- Volume
- 11
- Issue
- 11
- Pages
- 2465-2476
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC7547931
- OpenAlex
- W3089094100
- Cited by
- 35
- References
- 35
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 9 · 2023: 6 · 2022: 5 · 2021: 2
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Lirias (submittedVersion, cc-by-nc)
- Työväentutkimus Vuosikirja (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- Novartis, Basel, Switzerland
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, early combination therapy, vildagliptin, metformin, glycemic control, HbA1c, clinical inertia, newly diagnosed diabetes, insulin requirement, antidiabetic drugs, treatment failure, disease management, early detection of diabetes, tolerability, cost-effectiveness, quality of life
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes. https://app.cochat.ai/papers/10.1007/s13300-020-00926-7
- The paper
- Matthews, D., Del Prato, S., Mohan, V., Mathieu, C., Vencio, S., Chan, J. C. N., Stumvoll, M., & Paldánius, P. M. (2020). Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes. Diabetes Therapy. https://doi.org/10.1007/s13300-020-00926-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.